w

Jef Akst

| 1 min read

Register for free to listen to this article

Listen with Speechify

0:00

1:00

Share

w

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Jef Akst
Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
View full profile

Share

Related Research Resources

January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue

Research Resources

Sex Differences in Neurological Research

Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.

New Frontiers in Vaccine Development

Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.

New Approaches for Decoding Cancer at the Single-Cell Level

In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.

Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research

Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.

Products

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development

Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.

We’ve updated our Privacy Policy to make it clearer how we use your personal data.

Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.

w